Owned by Boehringer Ingelheim, Biosimilars Business Unit is a new company that is paving the way to be leaders of the Biosimilars industry. Due to common misconceptions that Biosimilars are cheap, easy to make and inferior to the drugs they are modelled from, this brand identity aims to convey the unique set of expertise approach that goes into the process of making and distributing the product. 

The BBU strives to provide quality and available treatments to sufferers of Cancer, Arthritis, skin, blood and gut diseases that might not have access to regular expensive drugs. This brand identity reflects that through an emphasis on accessibility and relatability. Pairing professionalism with a personal touch.